NeurAxon
closedNeurAxon discovers and develops pain therapeutics targeted on neuronal nitric oxide synthase.
Launch date
Employees
Market cap
-
Enterprise valuation
$3—5m (Dealroom.co estimates May 2012.)
Toronto Ontario (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.5m | Series A | ||
$32.0m | Series B | ||
| N/A | $8.8m | Debt | |
$14.0m | Debt | ||
| N/A | $780k | Seed | |
| Total Funding | $35.3m | ||
Related Content
Recent News about NeurAxon
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.